Sandbox/intraabdominal: Difference between revisions

Jump to navigation Jump to search
Guillermo Rodriguez Nava (talk | contribs)
No edit summary
Guillermo Rodriguez Nava (talk | contribs)
No edit summary
Line 1: Line 1:


===Initial Empiric Treatment of Extra-biliary Complicated Intra-abdominal Infection===
===Initial Empiric Treatment of Extra-biliary Community-acquired Complicated Intra-abdominal Infection===


{|
| valign=top |
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
'''Multidrug resistant gram-negative bacilli'''
</font>
</div>
<div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background:#4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Regimen'''
</font>
</div>
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
'''ESBL-Enterobacteriaceae'''
</font>
</div>
<div class="mw-customtoggle-table03" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background:#4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Regimen'''
</font>
</div>
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
'''[[''P. aeruginosa'']] >20% resistant to ceftazidime'''
</font>
</div>
<div class="mw-customtoggle-table05" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Regimen'''
</font>
</div>
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
'''[[MRSA]]'''
</font>
</div>
<div class="mw-customtoggle-table06" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Regimen'''
</font>
</div>
| valign=top |
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table01" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Single agent}}
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ertapenem]] 3 months to 12 years 15 mg/kg IV q12h; >13 years 1 g IV q24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Meropenem]] 60 mg/kg/day IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Imipenem]]/[[Cilastatin]] 60-100 mg/kg/day IV q4-6h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ticarcillin]]-[[Clavulanate]] 200-300 mg/kg/day IV q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Piperacillin]]-[[Tazobactam]] 200-300 mg/kg/day IV q6-8h'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table02" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Combination}}
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftriaxone]] 50-70 mg/kg/day IV q12-24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefotaxime]] 150-200 mg/kg/day IV q6-8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefepime]] 100 mg/kg/day IV q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftazidime]] 150 mg/kg/day IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 30-40 mg/kg/day IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''OR'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Gentamicin]] 3-7.5 mg/kg/day IV q2-4h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[tobramycin]] 3-7.5 mg/kg/day IV q8-24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 30-40 mg/kg/day IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 20-40 mg/kg/day IV q6-8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | WITH OR WITHOUT
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q8-24h'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table03" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Single agent}}
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefoxitin]] 2 g IV q6h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ertapenem]] 1 g IV q24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Tigecycline]] 100 mg initial dose, then 50 mg IV q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ticarcillin]]-[[Clavulanic acid]] 200 mg/kg/day IV q6h'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table04" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Combination}}
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefazolin]] 1-2 g IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefuroxime]] 1.5 g IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftriaxone]] 1-2 g IV q12-24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefotaxime]] 1-2 g IV q6-8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 400 mg IV q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Levofloxacin]] 750 mg IV q24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 500 mg IV q8-12h or 1.5 g q24h'''''
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table05" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Single agent}}
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Imipenem]]-[[Cilastatin]] 500 g IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Meropenem]] 1 g IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doripenem]] 500 g IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Piperacillin]]-[[Tazobactam]] 3.375 g IV q6h<sup>†</sup>'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <SMALL><sup>†</sup> For ''[[Pseudomonas aeruginosa]]'' may be increased to 3.375 g q4h or 4.5 g q6h .</SMALL>
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table06" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Combination}}
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefepime]] 2 g IV q8-12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftazidime]] 2 g IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 400 g IV q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Levofloxacin]] 750 mg IV q24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 500 mg IV q8-12h or 1.5 g q24h'''''
|-
|}
|}
|}
===Empiric Antimicrobial Therapy for Health Care–Associated Complicated Intra-abdominal Infection===


{|
{|

Revision as of 16:43, 12 June 2014

Initial Empiric Treatment of Extra-biliary Community-acquired Complicated Intra-abdominal Infection

Multidrug resistant gram-negative bacilli

  ▸  Regimen

ESBL-Enterobacteriaceae

  ▸  Regimen

''P. aeruginosa'' >20% resistant to ceftazidime

  ▸  Regimen

  ▸  Regimen

Single agent
Ertapenem 3 months to 12 years 15 mg/kg IV q12h; >13 years 1 g IV q24h
OR
Meropenem 60 mg/kg/day IV q8h
OR
Imipenem/Cilastatin 60-100 mg/kg/day IV q4-6h
OR
Ticarcillin-Clavulanate 200-300 mg/kg/day IV q12h
OR
Piperacillin-Tazobactam 200-300 mg/kg/day IV q6-8h
Combination
Ceftriaxone 50-70 mg/kg/day IV q12-24h
OR
Cefotaxime 150-200 mg/kg/day IV q6-8h
OR
Cefepime 100 mg/kg/day IV q12h
OR
Ceftazidime 150 mg/kg/day IV q8h
PLUS
Metronidazole 30-40 mg/kg/day IV q8h
OR
Gentamicin 3-7.5 mg/kg/day IV q2-4h
OR
tobramycin 3-7.5 mg/kg/day IV q8-24h
PLUS
Metronidazole 30-40 mg/kg/day IV q8h
OR
Clindamycin 20-40 mg/kg/day IV q6-8h
WITH OR WITHOUT
Ampicillin 200 mg/kg/day IV q8-24h
Single agent
Cefoxitin 2 g IV q6h
OR
Ertapenem 1 g IV q24h
OR
Moxifloxacin 400 mg IV q24h
OR
Tigecycline 100 mg initial dose, then 50 mg IV q12h
OR
Ticarcillin-Clavulanic acid 200 mg/kg/day IV q6h
Combination
Cefazolin 1-2 g IV q8h
OR
Cefuroxime 1.5 g IV q8h
OR
Ceftriaxone 1-2 g IV q12-24h
OR
Cefotaxime 1-2 g IV q6-8h
OR
Ciprofloxacin 400 mg IV q12h
OR
Levofloxacin 750 mg IV q24h
PLUS
Metronidazole 500 mg IV q8-12h or 1.5 g q24h
Single agent
Imipenem-Cilastatin 500 g IV q8h
OR
Meropenem 1 g IV q8h
OR
Doripenem 500 g IV q8h
OR
Piperacillin-Tazobactam 3.375 g IV q6h
For Pseudomonas aeruginosa may be increased to 3.375 g q4h or 4.5 g q6h .
Combination
Cefepime 2 g IV q8-12h
OR
Ceftazidime 2 g IV q8h
OR
Ciprofloxacin 400 g IV q12h
OR
Levofloxacin 750 mg IV q24h
PLUS
Metronidazole 500 mg IV q8-12h or 1.5 g q24h

Empiric Antimicrobial Therapy for Health Care–Associated Complicated Intra-abdominal Infection

Pediatric patients

  ▸  Single agent

  ▸  Combination

Adults, mild-to-moderate severity

  ▸  Single agent

  ▸  Combination

Adults, high risk or severity

  ▸  Single agent

  ▸  Combination

Single agent
Ertapenem 3 months to 12 years 15 mg/kg IV q12h; >13 years 1 g IV q24h
OR
Meropenem 60 mg/kg/day IV q8h
OR
Imipenem/Cilastatin 60-100 mg/kg/day IV q4-6h
OR
Ticarcillin-Clavulanate 200-300 mg/kg/day IV q12h
OR
Piperacillin-Tazobactam 200-300 mg/kg/day IV q6-8h
Combination
Ceftriaxone 50-70 mg/kg/day IV q12-24h
OR
Cefotaxime 150-200 mg/kg/day IV q6-8h
OR
Cefepime 100 mg/kg/day IV q12h
OR
Ceftazidime 150 mg/kg/day IV q8h
PLUS
Metronidazole 30-40 mg/kg/day IV q8h
OR
Gentamicin 3-7.5 mg/kg/day IV q2-4h
OR
tobramycin 3-7.5 mg/kg/day IV q8-24h
PLUS
Metronidazole 30-40 mg/kg/day IV q8h
OR
Clindamycin 20-40 mg/kg/day IV q6-8h
WITH OR WITHOUT
Ampicillin 200 mg/kg/day IV q8-24h
Single agent
Cefoxitin 2 g IV q6h
OR
Ertapenem 1 g IV q24h
OR
Moxifloxacin 400 mg IV q24h
OR
Tigecycline 100 mg initial dose, then 50 mg IV q12h
OR
Ticarcillin-Clavulanic acid 200 mg/kg/day IV q6h
Combination
Cefazolin 1-2 g IV q8h
OR
Cefuroxime 1.5 g IV q8h
OR
Ceftriaxone 1-2 g IV q12-24h
OR
Cefotaxime 1-2 g IV q6-8h
OR
Ciprofloxacin 400 mg IV q12h
OR
Levofloxacin 750 mg IV q24h
PLUS
Metronidazole 500 mg IV q8-12h or 1.5 g q24h
Single agent
Imipenem-Cilastatin 500 g IV q8h
OR
Meropenem 1 g IV q8h
OR
Doripenem 500 g IV q8h
OR
Piperacillin-Tazobactam 3.375 g IV q6h
For Pseudomonas aeruginosa may be increased to 3.375 g q4h or 4.5 g q6h .
Combination
Cefepime 2 g IV q8-12h
OR
Ceftazidime 2 g IV q8h
OR
Ciprofloxacin 400 g IV q12h
OR
Levofloxacin 750 mg IV q24h
PLUS
Metronidazole 500 mg IV q8-12h or 1.5 g q24h